<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149497">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01683188</url>
  </required_header>
  <id_info>
    <org_study_id>12PLK01</org_study_id>
    <nct_id>NCT01683188</nct_id>
  </id_info>
  <brief_title>HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma</brief_title>
  <acronym>PROCLIVITY 01</acronym>
  <official_title>A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prometheus Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prometheus Laboratories</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to evaluate treatment of metastatic melanoma patients with a
      combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®)
      and High Dose Interleukin-2 (abbreviated as HD IL-2 and known as Proleukin®). The
      combination of vemurafenib and HD IL-2 immunotherapy may enhance the response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label, uncontrolled two-arm, multi-center study in patients with
      metastatic melanoma with BRAFV600 oncogene mutations. Patients will initially receive
      treatment with vemurafenib interspersed with two courses of High Dose IL-2 (HD IL-2).
      Patients are eligible for the study if they have melanoma positive for the BRAFV600
      mutation, have been on vemurafenib therapy for 0-18 weeks, have responding or stable disease
      if on vemurafenib, and meet the requirements for dosing with HD IL-2 and all protocol
      inclusion and exclusion criteria.

      Two Cohorts will be enrolled, differing only in how they are characterized prior to HD IL-2
      treatment:

      Cohort 1:  will consist of 135 patients naïve to vemurafenib and HD IL-2 therapy.  Patients
      in Cohort 1 will have an initial evaluation and receive a defined 6 (± 1) week course of
      vemurafenib before beginning HD IL-2.  This Cohort will be used to define study size and
      statistical validity with the comparator being historic controls (using data from the BRAF
      positive patients from the Melanoma SELECT study Protocol IIT10PLK06).

      Cohort 2:  will consist of up to 50 patients who have been on vemurafenib therapy for &gt;7 to
      18 weeks with stable or responding disease before starting HD IL-2. Patients in Cohort 2
      will have an initial evaluation and will begin HD IL-2 treatment after &gt;7 to 18 weeks of
      treatment with vemurafenib.  This Cohort is designed to evaluate whether additive or
      synergistic clinical benefit or toxicity is observed in BRAFV600 mutation positive
      metastatic melanoma patients treated with vemurafenib as a single agent for &gt;7 to18 weeks
      prior to the first course of HD IL-2 therapy in conjunction with continued vemurafenib.

      Patients in both cohorts will discontinue dosing vemurafenib prior to each treatment with HD
      IL-2 and resume dosing after each discharge. Patients will receive up to two courses (four
      cycles) of HD IL-2 and will be evaluated for their disease responses at 10 weeks (±3 weeks)
      from the start of HD IL-2 dosing, and 26 weeks (±3 weeks) from the start of HD IL-2 dosing.
      QTc intervals will be reviewed daily for changes during each cycle of HD IL-2 dosing.

      Administration of vemurafenib and HD IL-2 will be according to the respective Package
      Inserts and according to the Institution's standard of care.  The investigator will
      determine the number of HD IL-2 cycles each patient will receive, according to the
      investigator's discretion and medical judgment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Assess Complete Response (CR) rate in BRAFV600 mutation positive metastatic melanoma patients who have received vemurafenib plus HD IL-2 at 10 (±3) weeks and 26 (±3) weeks from the start of HD IL-2 dosing.</measure>
    <time_frame>10 weeks, 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who have receive &gt;7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vemurafenib + HD IL-2</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years of age or older.

          -  Confirmed and measurable metastatic melanoma with the BRAFV600 mutation.

          -  Patients with at least one metastatic melanoma lesion accessible. for biopsy prior to
             vemurafenib treatment if no archived tissue is available.

          -  Meet the requirements for HD IL-2 therapy per institutional guidelines.

          -  Meet the requirements for vemurafenib therapy per institutional guidelines.

          -  Patient must be willing to provide written Informed Consent and participate in study
             procedures as described in the 12PLK01. Patients consented for 12PLK01 will also be
             asked to participate in the 10PLK13 PROCLAIM (Proleukin®) registry study.

        Exclusion Criteria:

          -  A patient will not be considered eligible for study participation if any of the
             following exclusion criteria are met:

          -  Prior therapy of metastatic disease with any of the following: IL-2, Ipilimumab, or
             other highly selective BRAF, MEK, NRAS, cMET inhibitors (e.g. GSK2118436 or
             GSK1120212) and TKIs.

               -  Exception: with a  6 week washout the following are allowed:

                    -  Adjuvant Ipilimumab,

                    -  Anti PD-1, Anti PD L-1

          -  Exclusion for Cohort 1 only: vemurafenib treatment &gt;7 weeks.

          -  Exclusion for Cohort 2 only: vemurafenib treatment &lt;7 weeks. (eligible for Cohort 1)
             or &gt;18 weeks.

          -  QTc interval of &gt;500ms.

          -  Patients with known or suspected infection with human immunodeficiency virus (HIV),
             hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis.

          -  Pregnant, nursing or planning to become pregnant.

          -  Untreated brain metastases.  (Brain metastases that have been treated, which no
             longer require corticosteroid therapy and are without progression by MRI assessment
             at least 6 weeks after definitive therapy are acceptable.)

          -  Received investigational drug within 30 days prior to study dosing.  Patients may
             participate in non-interventional or observational clinical study (ies)

          -  Concomitant disease or condition that would interfere with the conduct of the study
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the
             patient in this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Lowder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prometheus Laboratories</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa Luna</last_name>
    <phone>858-882-8058</phone>
    <email>tluna@prometheuslabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bauland</last_name>
      <phone>520-694-0859</phone>
      <email>abauland@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Cranmer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanna Lee, MPH</last_name>
      <phone>858-822-4171</phone>
      <email>sml012@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Daniels, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSMC Research Program</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Nunez, BSHSA</last_name>
      <phone>305-674-2625</phone>
      <email>yenrique@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Jose Lutzky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Kurilo, MPH</last_name>
      <phone>404-778-1842</phone>
      <email>tkurilo@emory.edu</email>
    </contact>
    <investigator>
      <last_name>David Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center, Div of Hematology/Oncology</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann L Clark, RN, BSN, MSN, CCRC, CCRP</last_name>
      <phone>(708) 327 3221</phone>
      <email>alausch@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luther General Cancer Care Institute</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Kanevsky, MD, CRA, Primary Study Coord.</last_name>
      <phone>847-410-0660</phone>
      <email>gkanevsky@oncmed.net</email>
    </contact>
    <investigator>
      <last_name>Sigrun Hallmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Niland, RN, BSN, OCN</last_name>
      <phone>317-278-0778</phone>
    </contact>
    <investigator>
      <last_name>Theodore Logan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Frees, RN</last_name>
      <phone>319-356-1228</phone>
      <email>melanie-frees@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Milhem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evie Key, RN, BSN, BA</last_name>
      <phone>225-767-0822</phone>
      <email>eviekey@hoc.brcoxmail.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Miletello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Patton, RN</last_name>
      <phone>734-936-8773</phone>
    </contact>
    <investigator>
      <last_name>Christopher D. Lao, MD, MPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Flaherty, MD</last_name>
      <phone>313-576-8725</phone>
      <email>flaherty@karmanos.org</email>
    </contact>
    <contact_backup>
      <phone>800-527-6266</phone>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Flaherty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie McCann, RN</last_name>
      <phone>612-626-2569</phone>
      <email>mcca0313@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Venkatesh Rudrapatna, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eryn Bagley</last_name>
      <phone>603-650-4035</phone>
      <email>eryn.m.bagley@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Marc S Ernstoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Blair, RN, BSN, OCN</last_name>
      <phone>551-996-5809</phone>
      <email>dblair@hackensackumc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Alter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amiya R. Vaz</last_name>
      <phone>212-305-1317</phone>
      <email>av2454@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Taback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Manfresca, RN, BSN, OCN</last_name>
      <phone>513-585-0844</phone>
      <email>pam.manfresca@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Philip Leming, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Prots, RN</last_name>
      <phone>216-844-5393</phone>
      <email>Donna.prots@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Henry Koon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Fountain, RN, OCN</last_name>
      <phone>503-215-2691</phone>
      <email>christopher.fountain@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital, Anderson Campus</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Cabral</last_name>
      <phone>484-503-4151</phone>
      <email>Rosemarie.Cabral@sluhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Max, MS, CCRP</last_name>
      <phone>484-526-5190</phone>
      <email>Tracy.Max@sluhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjiv Agarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mollie Maguire, RN, BSN</last_name>
      <phone>412-623-4004</phone>
      <email>maguiremd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Kirkwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>skin cancer</keyword>
  <keyword>Stage IV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
